Natural infection as a blueprint for rational HIV vaccine design

References

• Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9; PMID:18558875; http://dx.doi.org/10.1086/589862
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; http://dx.doi.org/10.1086/428404
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in bangkok, thailand. J Infect Dis 2006; 194:1661-71; PMID:17109337; http://dx.doi.org/10.1086/508748
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and phambili trial results: Two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5:357-61; PMID:20978374; http://dx.doi.org/10.1097/COH.0b013e32833d2d2b
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al. Safety and efficacy of the HVTN 503/phambili study of a clade-B-based HIV-1 vaccine in south africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-15; PMID:21570355; http://dx.doi.org/10.1016/S1473-3099(11)70098-6
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-92; PMID:24099601; http://dx.doi.org/10.1056/NEJMoa1310566
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004; 37:1160-5; PMID:15319676; http://dx.doi.org/10.1097/01.qai.0000136091.72955.4b
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425
   PubMed Web of Science ®Google Scholar
• Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, et al. The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444-57; PMID:23035746; http://dx.doi.org/10.1089/aid.2012.0103
   PubMed Web of Science ®Google Scholar
• Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013; 110:9019-24; PMID:23661056; http://dx.doi.org/10.1073/pnas.1301456110
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, Haynes BF, Moody MA. HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design. Trends Microbiol 2012; 20:532-9; PMID:22981828; http://dx.doi.org/10.1016/j.tim.2012.08.011
   PubMed Web of Science ®Google Scholar
• Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358:1590-602; PMID:18403767; http://dx.doi.org/10.1056/NEJMra0706737
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433; PMID:19436712; http://dx.doi.org/10.1371/journal.ppat.1000433
   PubMed Web of Science ®Google Scholar
• Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181-6; http://dx.doi.org/10.1073/pnas.1103012108
   PubMed Web of Science ®Google Scholar
• Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 2014; 211:2061-74; PMID:25155019; http://dx.doi.org/10.1084/jem.20132494
   PubMed Web of Science ®Google Scholar
• Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7; PMID:18490657; http://dx.doi.org/10.1073/pnas.0802203105
   PubMed Web of Science ®Google Scholar
• Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T, Schuitemaker H. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol 2012; 86:2045-55; PMID:22156522; http://dx.doi.org/10.1128/JVI.06091-11
   PubMed Web of Science ®Google Scholar
• Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82:7932-41; PMID:18524815; http://dx.doi.org/10.1128/JVI.00757-08
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Morris L, Ferrari G, Mascola JR. Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS 2007; 2:169-76; PMID:19372883; http://dx.doi.org/10.1097/COH.0b013e3280ef691e
   PubMed Web of Science ®Google Scholar
• Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: Evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006; 80:6155-64; PMID:16731954; http://dx.doi.org/10.1128/JVI.00093-06
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-12; PMID:12646921; http://dx.doi.org/10.1038/nature01470
   PubMed Web of Science ®Google Scholar
• Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:3734-41; PMID:9094648
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013; 9:e1003738; PMID:24204277; http://dx.doi.org/10.1371/journal.ppat.1003738
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009; 23:2405-14; PMID:19770692; http://dx.doi.org/10.1097/QAD.0b013e32833243e7
   PubMed Web of Science ®Google Scholar
• Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med 2015; 21:1332-6; PMID:26457756; http://dx.doi.org/10.1038/nm.3963
   PubMed Web of Science ®Google Scholar
• Benjelloun F, Lawrence P, Verrier B, Genin C, Paul S. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J Virol 2012; 86:13152-63; PMID:23015715; http://dx.doi.org/10.1128/JVI.01110-12
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 2010; 10:527-35; PMID:20577269; http://dx.doi.org/10.1038/nri2801
   PubMed Web of Science ®Google Scholar
• Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, Cupo A, Julien JP, van Gils M, Lee PS, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 env trimers. Immunity 2014; 40:669-80; PMID:24768348; http://dx.doi.org/10.1016/j.immuni.2014.04.008
   PubMed Web of Science ®Google Scholar
• Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014; 40:657-68; PMID:24768347; http://dx.doi.org/10.1016/j.immuni.2014.04.009
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology 2013; 435:46-56; PMID:23217615; http://dx.doi.org/10.1016/j.virol.2012.10.004
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-76; PMID:23552890; http://dx.doi.org/10.1038/nature12053
   PubMed Web of Science ®Google Scholar
• Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18:1688-92; PMID:23086475; http://dx.doi.org/10.1038/nm.2985
   PubMed Web of Science ®Google Scholar
• Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, et al. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-48; PMID:19439467; http://dx.doi.org/10.1128/JVI.00110-09
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Barbas C, Burton DR, Wilson IA. Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: An antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallographica Section D: Biological Crystallography 2001; 57:168-71; http://dx.doi.org/10.1107/S0907444900017376
   PubMed Web of Science ®Google Scholar
• Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-38; PMID:23540694; http://dx.doi.org/10.1016/j.cell.2013.03.018
   PubMed Web of Science ®Google Scholar
• Sather DN, Carbonetti S, Malherbe D, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, et al. Emergence of broadly neutralizing antibodies and viral co-evolution in two subjects during the early stages of infection with the human immunodeficiency virus type 1. J Virol 2014; 88(22):12968-81; PMID:25122781
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509:55-62; PMID:24590074; http://dx.doi.org/10.1038/nature13036
   PubMed Web of Science ®Google Scholar
• Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, Song H, Zhou T, et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014; 158:481-91; PMID:25065977; http://dx.doi.org/10.1016/j.cell.2014.06.022
   PubMed Web of Science ®Google Scholar
• Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog 2015; 11:e1004767; PMID:25807248; http://dx.doi.org/10.1371/journal.ppat.1004767
   PubMed Web of Science ®Google Scholar
• Verkoczy L, Kelsoe G, Moody MA, Haynes BF. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2011; 23:383-90; PMID:21524897; http://dx.doi.org/10.1016/j.coi.2011.04.003
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-70; PMID:21849977; http://dx.doi.org/10.1038/nature10373
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol 2015; 90:76-91; PMID:26468542; http://dx.doi.org/10.1128/JVI.01791-15
   PubMed Web of Science ®Google Scholar
• Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013; 9:e1003342; PMID:23658524; http://dx.doi.org/10.1371/journal.ppat.1003342
   PubMed Web of Science ®Google Scholar
• Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334:1097-103; PMID:21998254; http://dx.doi.org/10.1126/science.1213256
   PubMed Web of Science ®Google Scholar
• Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination. Curr Opin HIV AIDS 2014; 9:224-34; PMID:24714565; http://dx.doi.org/10.1097/COH.0000000000000049
   PubMed Web of Science ®Google Scholar
• Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78:10724-37; PMID:15367639; http://dx.doi.org/10.1128/JVI.78.19.10724-10737.2004
   PubMed Web of Science ®Google Scholar
• Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22:163-73; PMID:15723805; http://dx.doi.org/10.1016/j.immuni.2004.12.011
   PubMed Web of Science ®Google Scholar
• Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies 2005; 14:59-67; PMID:16720975
   PubMedGoogle Scholar
• Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 2015; 89:784-98; PMID:25355869; http://dx.doi.org/10.1128/JVI.02378-14
   PubMed Web of Science ®Google Scholar
• Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci 2012; 69:1435-45; PMID:22045557; http://dx.doi.org/10.1007/s00018-011-0872-6
   PubMed Web of Science ®Google Scholar
• Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-45; PMID:19319142; http://dx.doi.org/10.1038/nri2524
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Mascola JR. HIV immunology goes out on a limb. Immunity 2016; 44:1088-90; PMID:27192575; http://dx.doi.org/10.1016/j.immuni.2016.05.004
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85:9998-10009; PMID:21795340; http://dx.doi.org/10.1128/JVI.05045-11
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, Ozorowski G, Chuang GY, Schramm CA, Wiehe K, et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 2016; 165:449-63; PMID:26949186; http://dx.doi.org/10.1016/j.cell.2016.02.022
   PubMed Web of Science ®Google Scholar
• Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 2013; 9:e1003754; PMID:24278016
   PubMed Web of Science ®Google Scholar
• MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, et al. Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the env high-mannose patch. Immunity 2016; 44:1215-26; PMID:27192579; http://dx.doi.org/10.1016/j.immuni.2016.04.016
   PubMed Web of Science ®Google Scholar
• Ward AB, Wilson IA. Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci 2015; 40:101-7; PMID:25600289; http://dx.doi.org/10.1016/j.tibs.2014.12.006
   PubMed Web of Science ®Google Scholar
• Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 env. Nature 2014; 514:455-61; PMID:25296255; http://dx.doi.org/10.1038/nature13808
   PubMed Web of Science ®Google Scholar
• Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, Wang Y. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 2013; 10:14; PMID:23384254; http://dx.doi.org/10.1186/1742-4690-10-14
   PubMed Web of Science ®Google Scholar
• Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-44; PMID:20192810; http://dx.doi.org/10.1146/annurev-immunol-030409-101256
   PubMed Web of Science ®Google Scholar
• Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202:595-605; PMID:20608874; http://dx.doi.org/10.1086/654816
   PubMed Web of Science ®Google Scholar
• Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 2012; 109:12111-6; PMID:22773820; http://dx.doi.org/10.1073/pnas.1204533109
   PubMed Web of Science ®Google Scholar
• Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001; 75:645-53; PMID:11134278; http://dx.doi.org/10.1128/JVI.75.2.645-653.2001
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2000; 16:981-94; PMID:10890360; http://dx.doi.org/10.1089/08892220050058407
   PubMed Web of Science ®Google Scholar
• Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR, Parren PW, Binley JM, Roux KH, et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002; 76:7760-76; PMID:12097589; http://dx.doi.org/10.1128/JVI.76.15.7760-7776.2002
   PubMed Web of Science ®Google Scholar
• Yang X, Farzan M, Wyatt R, Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000; 74:5716-25; PMID:10823881; http://dx.doi.org/10.1128/JVI.74.12.5716-5725.2000
   PubMed Web of Science ®Google Scholar
• Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002; 76:4634-42; PMID:11932429; http://dx.doi.org/10.1128/JVI.76.9.4634-4642.2002
   PubMed Web of Science ®Google Scholar
• Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203:1165-73; PMID:21451004; http://dx.doi.org/10.1093/infdis/jiq175
   PubMed Web of Science ®Google Scholar
• Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002; 76:8875-89; PMID:12163607; http://dx.doi.org/10.1128/JVI.76.17.8875-8889.2002
   PubMed Web of Science ®Google Scholar
• Sanders RW, Derking R, Cupo A, Julien J, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña A T, Korzun J. A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS pathogens 2013; 9:e1003618; PMID:24068931; http://dx.doi.org/10.1371/journal.ppat.1003618
   PubMed Web of Science ®Google Scholar
• Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, Dubrovskaya V, Ward AB, Wyatt RT. Cleavage-independent HIV-1 env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep 2015; 11:539-50; PMID:25892233; http://dx.doi.org/10.1016/j.celrep.2015.03.047
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 2015; 349:320-4; PMID:26138104; http://dx.doi.org/10.1126/science.aab3886
   PubMed Web of Science ®Google Scholar
• Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran H, Mach LV, Lifton MA, Pantaleo G, Tartaglia J, et al. Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and envelope protein boost. J Virol 2015; 89:6462-80; PMID:25855741; http://dx.doi.org/10.1128/JVI.00383-15
   PubMed Web of Science ®Google Scholar
• Sliepen K, Sanders RW. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines 2016; 15:349-65; PMID:26654478
   PubMed Web of Science ®Google Scholar
• Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015; 349:aac4223; PMID:26089353; http://dx.doi.org/10.1126/science.aac4223
   PubMed Web of Science ®Google Scholar
• Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, et al. Immunization for HIV-1 broadly neutralizing antibodies in human ig knockin mice. Cell 2015; 161:1505-15; PMID:26091035; http://dx.doi.org/10.1016/j.cell.2015.06.003
   PubMed Web of Science ®Google Scholar
• Sliepen K, Ozorowski G, Burger JA, van Montfort T, Stunnenberg M, LaBranche C, Montefiori DC, Moore JP, Ward AB, Sanders RW. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology 2015; 12:82; PMID:26410741; http://dx.doi.org/10.1186/s12977-015-0210-4
   PubMed Web of Science ®Google Scholar
• Ingale J, Stano A, Guenaga J, Sharma SK, Nemazee D, Zwick MB, Wyatt RT. High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells. Cell Rep 2016; 15:1986-99; PMID:27210756; http://dx.doi.org/10.1016/j.celrep.2016.04.078
   PubMed Web of Science ®Google Scholar
• Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711-6; PMID:23539181; http://dx.doi.org/10.1126/science.1234150
   PubMed Web of Science ®Google Scholar
• Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, Thinnes TC, Bhullar D, Briney B, et al. HIV-1 VACCINES. priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015; 349:156-61; PMID:26089355; http://dx.doi.org/10.1126/science.aac5894
   PubMed Web of Science ®Google Scholar
• Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, Lu X, Sutherland LL, Scearce RM, Bowman C, et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 2013; 87:4185-201; PMID:23365441; http://dx.doi.org/10.1128/JVI.02297-12
   PubMed Web of Science ®Google Scholar
• Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K, et al. A multivalent clade C HIV-1 env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol 2015; 89:2507-19; PMID:25540368; http://dx.doi.org/10.1128/JVI.03331-14
   PubMed Web of Science ®Google Scholar
• Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011; 85:5262-74; PMID:21430056; http://dx.doi.org/10.1128/JVI.02419-10
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423-33; PMID:22565972; http://dx.doi.org/10.1038/nbt.2197
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-63; PMID:21314428; http://dx.doi.org/10.1146/annurev-immunol-031210-101400
   PubMed Web of Science ®Google Scholar
• Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, Flanders MD, Cutler S, Yudanin N, Muller MI, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012; 122:3271-80; PMID:22922259; http://dx.doi.org/10.1172/JCI64314
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Lynch RM, Gautam R, Matus-Nicodemos R, Schmidt SD, Boswell KL, Darko S, Wong P, Sheng Z, Petrovas C, et al. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med 2015; 7:298ra120; PMID:26223303; http://dx.doi.org/10.1126/scitranslmed.aab3964
   PubMed Web of Science ®Google Scholar
• Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, Metcalf T, Connick E, Meditz A, Freeman GJ, Abesada-Terk G, Jr, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19:494-9; PMID:23475201; http://dx.doi.org/10.1038/nm.3109
   PubMed Web of Science ®Google Scholar
• Cubas R, Perreau M. The dysfunction of T follicular helper cells. Curr Opin HIV AIDS 2014; 9:485-91; PMID:25023620; http://dx.doi.org/; http://dx.doi.org/10.1097/COH.0000000000000095
   PubMed Web of Science ®Google Scholar
• de Bree GJ, Lynch RM. B cells in HIV pathogenesis. Curr Opin Infect Dis 2016; 29:23-30; PMID:26658653; http://dx.doi.org/10.1097/QCO.0000000000000225
   PubMed Web of Science ®Google Scholar
• Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, Su LF, Cubas R, Davis MM, Sette A, et al. Human circulating PD-1+CXCR3-CXCR5+ memory tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39:758-69; PMID:24035365; http://dx.doi.org/10.1016/j.immuni.2013.08.031
   PubMed Web of Science ®Google Scholar